HYPK: A GPCR Involved in Cell Growth, Apoptosis and Angiogenesis

Target Name: HYPK

NCBI ID: G25764

HYPK

HYPK: A GPCR Involved in Cell Growth, Apoptosis and Angiogenesis

Human Yang-tansuic Kinase (HYPK) is a protein that plays a crucial role in the regulation of cell growth, apoptosis, and angiogenesis. It is a member of the tyrosine kinase family and is localized to the cytoplasm of various cell types. HYPK is involved in the regulation of many cellular processes, including cell adhesion, migration, and the response to stimuli.

HYPK is a protein that is expressed in many different tissues and cells throughout the body. It is highly homogeneous and has a calculated molecular weight of 48.1 kDa. HYPK is a G protein-coupled receptor (GPCR), which means that it can interact with intracellular signaling molecules, such as G protein-coupled receptors.

GPCRs are a family of transmembrane proteins that play a critical role in cellular signaling. They are characterized by the presence of an extracellular portion that is involved in the interaction with intracellular signaling molecules, as well as a transmembrane portion that contains the catalytic center of the protein.

HYPK is a member of the subfamily of GPCRs known as the Pycadherin superfamily. This family of proteins is characterized by the presence of a conserved catalytic core and a variety of unique features, such as the presence of a transmembrane portion that is involved in the regulation of protein function.

HYPK is involved in many different cellular processes, including cell adhesion, migration, and the response to stimuli. It is highly expressed in various tissues, including the brain, heart, and gastrointestinal tract. It is also involved in the regulation of many different signaling pathways, including the TGF-β pathway and the Wnt pathway.

HYPK is a potential drug target for a variety of diseases. Its involvement in cell adhesion and migration makes it a potential target for therapies that are designed to promote tissue repair and regeneration. HYPK is also involved in the regulation of cell apoptosis, which is the process by which cells die when they have reached their lifespan. Its involvement in this process makes it a potential target for therapies that are designed to prevent or reverse apoptosis.

In addition to its potential as a drug target, HYPK is also a potential biomarker for a variety of diseases. Its expression is often reduced in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This makes it a potential indicator of the presence of these diseases and could be used for diagnostic purposes.

Overall, HYPK is a protein that plays a critical role in the regulation of cell growth, apoptosis, and angiogenesis. Its involvement in these processes makes it a potential target for therapies that are designed to promote tissue repair and regeneration, as well as potential biomarkers for a variety of diseases. Further research is needed to fully understand the role of HYPK in these processes and to develop effective therapies.

Protein Name: Huntingtin Interacting Protein K

Functions: Component of several N-terminal acetyltransferase complexes (PubMed:20154145, PubMed:29754825, PubMed:32042062). Inhibits the N-terminal acetylation activity of the N-terminal acetyltransferase NAA10-NAA15 complex (also called the NatA complex) (PubMed:29754825, PubMed:32042062). Has chaperone-like activity preventing polyglutamine (polyQ) aggregation of HTT in neuronal cells probably while associated with the NatA complex (PubMed:17947297, PubMed:20154145). May play a role in the NatA complex-mediated N-terminal acetylation of PCNP (PubMed:20154145)

The "HYPK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HYPK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets